Evidence map›Paper›PMID 26575471›Full record

ArticleJournal of visualized experiments : JoVE2015

Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria.

Rachel Daniels, Elizabeth J Hamilton, Katelyn Durfee, Daouda Ndiaye, Dyann F Wirth, Daniel L Hartl, Sarah K Volkman

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Rachel DanielsDepartment of Organismic and Evolutionary Biology, Harvard University; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health; rdaniels@broadinstitute.org.
Elizabeth J HamiltonDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health.
Katelyn DurfeeDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health.
Daouda NdiayeFaculty of Medicine and Pharmacy, Cheikh Anta Diop University.
Dyann F WirthDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health; Institute of Infectious Diseases, Broad Institute.
Daniel L HartlDepartment of Organismic and Evolutionary Biology, Harvard University.
Sarah K VolkmanDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health; School of Nursing and Health Sciences, Simmons College.
Harvard University · USBroad Institute · USCheikh Anta Diop University · SN

Funding

Novel Genetic Mechanism of Artemisinin Resistance for MalariaR01AI099105 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HARTL, DANIEL L, WIRTH, DYANN F · 2013 to 2021
$5.4M
Evolutionary medicine in the development of antimalaria drugsR01AI106734 · NIAID · HARVARD UNIVERSITY · PI HARTL, DANIEL L · 2014 to 2017
$1.6M
NIAID NIH HHS R01 AI099105NIAID NIH HHS R01 AI106734
6 · The paper itself

Abstract

Despite decades of eradication efforts, malaria remains a global burden. Recent renewed interest in regional elimination and global eradication has been accompanied by increased genomic information about Plasmodium parasite species responsible for malaria, including characteristics of geographical populations as well as variations associated with reduced susceptibility to anti-malarial drugs. One common genetic variation, single-nucleotide polymorphisms (SNPs), offers attractive targets for parasite genotyping. These markers are useful not only for tracking drug resistance markers but also for tracking parasite populations using markers not under drug or other selective pressures. SNP genotyping methods offer the ability to track drug resistance as well as to fingerprint individual parasites for population surveillance, particularly in response to malaria control efforts in regions nearing elimination status. While informative SNPs have been identified that are agnostic to specific genotyping technologies, high-resolution melting (HRM) analysis is particularly suited to field-based studies. Compared to standard fluorescent-probe based methods that require individual SNPs in a single labeled probe and offer at best 10% sensitivity to detect SNPs in samples that contain multiple genomes (polygenomic), HRM offers 2-5% sensitivity. Modifications to HRM, such as blocked probes and asymmetric primer concentrations as well as optimization of amplification annealing temperatures to bias PCR towards amplification of the minor allele, further increase the sensitivity of HRM. While the sensitivity improvement depends on the specific assay, we have increased detection sensitivities to less than 1% of the minor allele. In regions approaching malaria eradication, early detection of emerging or imported drug resistance is essential for prompt response. Similarly, the ability to detect polygenomic infections and differentiate imported parasite types from cryptic local reservoirs can inform control programs. This manuscript describes modifications to high resolution melting technology that further increase its sensitivity to identify polygenomic infections in patient samples.

Indexed as

Polymorphism, Single NucleotideAllelesDNA, ProtozoanGenomicsGenotypeGenotyping TechniquesHumansMalariaMalaria, FalciparumPlasmodium falciparumPolymerase Chain ReactionSensitivity and SpecificityDNA, Protozoan

Identifiers

PMID26575471
PMCPMC4692701
OpenAlexW2180853018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.